Research programme: small molecule therapeutics - Syros Pharmaceuticals

Drug Profile

Research programme: small molecule therapeutics - Syros Pharmaceuticals

Alternative Names: CDK12/12 inhibitors - Syros Pharmaceuticals; Cyclin-dependent kinase 12/13 inhibitors - Syros Pharmaceuticals; SY 351; THZ1; THZ531

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syros Pharmaceuticals
  • Developer Dana-Farber Cancer Institute; Syros Pharmaceuticals; Whitehead Institute for Biomedical Research
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; Gene expression modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Breast cancer; Cancer; Ewing's sarcoma; Neuroblastoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Small cell lung cancer
  • Research Alzheimer's disease; Autoimmune disorders; Polycystic kidney disease; Sickle cell anaemia

Most Recent Events

  • 08 Jan 2018 Early research in Sickle cell anaemia in USA (unspecified route)
  • 15 May 2017 Syros pharmaceuticals plans to file an IND application with the USFDA in USA for Cancer
  • 03 Apr 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the presented at 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top